Firms to co-develop heart-failure drug in potential $430M deal

05/10/2013 | American City Business Journals

Trevena and Forest Laboratories entered into a licensing-option deal involving TRV027, Trevena's drug candidate for acute heart failure. Forest agreed to make a $30 million equity stake in Trevena in exchange for an option to license TRV027. If Forest exercises its option, Trevena will be entitled to as much as $430 million in milestone fees plus sales royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT